Drug intelligence / Profile preview

MBF-132

Development stage: Preclinical
Lead developer: Medibiofarma
Modality: Small Molecules
Administration: Oral

Overview

MBF-132 is a selective small molecule inhibitor of histone deacetylase 8 (HDAC8) under development by Medibiofarma. HDAC8 is a class I histone deacetylase that plays a key role in regulating gene expression and chromatin structure by deacetylating both histone and non-histone proteins. MBF-132 is being investigated in preclinical studies for the treatment of cancer and fibrosis, where HDAC8 activity is implicated in pathological cell proliferation, tissue remodeling, and fibrotic progression.

Targets

HDAC8 (Histone Deacetylase 8)

Beyond the preview

Go deeper on MBF-132.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBF-132.

Explore the full profile